Form 4: Jaguar Health CEO Granted Equity Awards

Jaguar Health's CEO and President, Lisa A. Conte, was granted 28,592 restricted stock units and 28,592 stock options on December 11, 2025, under the company's 2014 Stock Incentive Plan.

Summary

• Lisa A. Conte, CEO and President of Jaguar Health, Inc., received equity awards on December 11, 2025.
• The awards include 28,592 restricted stock units (RSUs) and 28,592 stock options.
• The RSUs represent a contingent right to receive one share of common stock each and will vest on December 11, 2026.
• The stock options have an exercise price of $1.44 per share and will vest ratably on a monthly basis over 12 months from the grant date.
• Both grants were approved by the issuer's board of directors and were made under the 2014 Stock Incentive Plan.
• Following these transactions, Lisa A. Conte beneficially owns 29,258 shares of common stock and 28,592 stock options directly.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of executive equity compensation, which is a neutral event. It reflects standard corporate governance and compensation practices without indicating any immediate positive or negative operational or financial news.

Positives

• The equity grants align management's interests with those of shareholders, incentivizing long-term performance.
• The grants were made under an existing, board-approved stock incentive plan, indicating standard corporate compensation practices.

Future Outlook

The filing indicates future vesting schedules for both restricted stock units (December 11, 2026) and stock options (ratably over 12 months from December 11, 2025), tying executive compensation to future company performance.

Management Comments

• Chief Exec. Officer & President

Industry Context

This is a routine executive compensation disclosure, common across publicly traded companies, reflecting standard practices for incentivizing leadership through equity awards. It does not provide specific industry-wide insights.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a CEO is a standard practice in executive compensation across various industries, including biotechnology and pharmaceuticals, to align executive incentives with shareholder value creation.
• The vesting schedules (one year for RSUs, monthly over 12 months for options) are typical for such awards, designed to encourage retention and long-term performance.
• The exercise price of $1.44 for the options would typically be the closing market price on the grant date, which is standard for at-the-money options.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Lisa A. Conte, the CEO and President, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's financial interests with long-term shareholder value creation, potentially leading to improved performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• The restricted stock units will vest on December 11, 2026.
• The stock options will vest ratably on a monthly basis over 12 months from December 11, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to an executive, which is a standard compensation practice and does not provide new information that would significantly alter the investment thesis for Jaguar Health. It is a neutral event that aligns executive incentives with shareholder interests but does not indicate any immediate operational or financial catalysts for a "buy" or "sell" recommendation. Therefore, a "hold" recommendation is appropriate, maintaining current positions while awaiting more substantive news.

Keywords

Jaguar Health, JAGX, Lisa A. Conte, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Grant, CEO Compensation, Executive Compensation, 10b5-1 Plan